Evidence map›Paper›PMID 36012638›Full record

ReviewInternational journal of molecular sciences2022

Breast Cancer-Delivered Exosomal miRNA as Liquid Biopsy Biomarkers for Metastasis Prediction: A Focus on Translational Research with Clinical Applicability.

Oana Baldasici, Valentina Pileczki, Daniel Cruceriu, Laura Ioana Gavrilas, Oana Tudoran, Loredana Balacescu, Laurian Vlase, Ovidiu Balacescu

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Circulating biomarkers for diagnosis and response to therapies in cancer patients.International review of cell and molecular biology · 2025
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Oana BaldasiciThe Oncology Institute "Prof. Dr. Ion Chiricuta", Department of Genetics, Genomics and Experimental Pathology, 400015 Cluj-Napoca, Romania.
Valentina PileczkiThe Oncology Institute "Prof. Dr. Ion Chiricuta", Department of Genetics, Genomics and Experimental Pathology, 400015 Cluj-Napoca, Romania.
Daniel CruceriuThe Oncology Institute "Prof. Dr. Ion Chiricuta", Department of Genetics, Genomics and Experimental Pathology, 400015 Cluj-Napoca, Romania.
Laura Ioana GavrilasDepartment of Bromatology, Hygiene, Nutrition, "Iuliu Hatieganu" University of Medicine and Pharmacy, 23 Marinescu Street, 400337 Cluj-Napoca, Romania.
Oana TudoranThe Oncology Institute "Prof. Dr. Ion Chiricuta", Department of Genetics, Genomics and Experimental Pathology, 400015 Cluj-Napoca, Romania.
Loredana BalacescuThe Oncology Institute "Prof. Dr. Ion Chiricuta", Department of Genetics, Genomics and Experimental Pathology, 400015 Cluj-Napoca, Romania.
Laurian VlaseDepartment of Pharmaceutical Technology and Biopharmaceutics, "Iuliu Haţieganu" University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania.ORCID 0000-0002-0664-3387
Ovidiu BalacescuThe Oncology Institute "Prof. Dr. Ion Chiricuta", Department of Genetics, Genomics and Experimental Pathology, 400015 Cluj-Napoca, Romania.ORCID 0000-0003-0253-7103
Institute of Oncology Prof. Dr. Ion Chiricuta · ROIuliu Hațieganu University of Medicine and Pharmacy · ROBabeș-Bolyai University · RO

Funding

POC Contract no. 41/ 02.09.2016UEFISCDI PN-III-P2-2.1-PED-2019-5128, grant number 556PED ⁄ 2020
6 · The paper itself

Abstract

Metastasis represents the most important cause of breast cancer-associated mortality. Even for early diagnosed stages, the risk of metastasis is significantly high and predicts a grim outcome for the patient. Nowadays, efforts are made for identifying blood-based biomarkers that could reliably distinguish patients with highly metastatic cancers in order to ensure a closer follow-up and a more personalized therapeutic method. Exosomes are nano vesicles secreted by cancer cells that can transport miRNAs, proteins, and other molecules and deliver them to recipient cells all over the body. Through this transfer, cancer cells modulate their microenvironment and facilitate the formation of the pre-metastatic niche, leading to sustained progression. Exosomal miRNAs have been extensively studied due to their promising potential as prognosis biomarkers for metastatic breast cancer. In this review, we tried to depict an overview of the existing literature regarding exosomal miRNAs that are already validated as potential biomarkers, and which could be immediately available for the clinic. Moreover, in the last section, we highlighted several miRNAs that have proven their function in preclinical studies and could be considered for clinical validation. Considering the lack of standard methods for evaluating exosomal miRNA, we also discussed the challenges and the technical aspects underlying this issue.

Indexed as

Breast NeoplasmsExosomesMicroRNAsBiomarkersBiomarkers, TumorFemaleHumansLiquid BiopsyTranslational Research, BiomedicalTumor MicroenvironmentBiomarkersBiomarkers, TumorMicroRNAsbiomarkerbreast cancerclinical applicabilityexosomesextracellular vesiclesmetastasismiRNAtranslational research

Identifiers

PMID36012638
PMCPMC9408950
OpenAlexW4293680115

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.